ORBIMED ADVISORS LLC 13D and 13G filings for Ikena Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-09-21 4:52 pm Sale |
2023-08-04 | 13D | Ikena Oncology, Inc. IKNA |
ORBIMED ADVISORS LLC | 2,189,111 5.200% |
-153,121 (-6.54%) |
Filing |
| 2023-09-14 4:21 pm Purchase |
2023-08-04 | 13D | Ikena Oncology, Inc. IKNA |
ORBIMED ADVISORS LLC | 2,342,232 5.500% |
405,346 (+20.93%) |
Filing |
| 2021-08-16 4:45 pm Unchanged |
2021-08-12 | 13D | Ikena Oncology, Inc. IKNA |
ORBIMED ADVISORS LLC | 1,936,886 5.400% |
0 (Unchanged) |
Filing |
| 2021-04-14 7:31 pm Purchase |
2021-03-30 | 13D | Ikena Oncology, Inc. IKNA |
ORBIMED ADVISORS LLC | 1,936,886 6.560% |
1,936,886 (New Position) |
Filing |